Comparative Pharmacology
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus CEFTRIAXONE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFAZOLIN IN DEXTROSE versus CEFTRIAXONE IN PLASTIC CONTAINER.
CEFAZOLIN IN DEXTROSE vs CEFTRIAXONE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby disrupting peptidoglycan cross-linking.
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 8 hours. For serious infections, up to 2 g IV every 6 hours.
1-2 g intravenously or intramuscularly every 12-24 hours, maximum 4 g daily.
None Documented
None Documented
1.8 hours in normal renal function. Prolonged to 12-24 hours in end-stage renal disease (CrCl <10 mL/min).
5.8-8.7 hours in adults; prolonged in neonates (18-25 h), elderly, and renal impairment.
Renal: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary: minor (<1%). Fecal: negligible.
Renal (33-67% as unchanged drug), biliary/fecal (24-44% as active drug and metabolites).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic